MedTrace Logo

Ketamine and Lidocaine Infusion in Refractory Chronic Migraine

NCT06935552 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2025-04-20

No results posted yet for this study

Summary

Ketamine and lidocaine infusion for refractory chronic migraine: Comparative Study

Conditions

  • Refractory Chronic Migraine

Interventions

DRUG

Ketamine infusion

group A will receive ketamine intravenous infusion

DRUG

Lidocaine Intravenous Infusion

group B will receive lidocaine intravenous infusion

DRUG

Dextrose 5% in water

group C will only receive Dextrose 5% in water

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Nageh Fouly Kamel, PhD. · Assiut University

  • Mohamed Ahmed Abdelhameed, PhD. · Assiut University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-01
Primary Completion
2026-11-30
Completion
2026-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06935552 on ClinicalTrials.gov